Literature DB >> 15042584

Translocation of protein kinase C-betaII in astrocytes requires organized actin cytoskeleton and is not accompanied by synchronous RACK1 relocation.

Alessia Pascale1, Daniel L Alkon, Maurizio Grimaldi.   

Abstract

Protein kinase C (PKC)-betaII is the most abundant PKC isoform in astrocytes. Upon activation, this isoform of PKC translocates from the cytosol to the plasma membrane (PM). In this study, we investigated in astrocytes the modality of PKC-betaII translocation as far as the participation of the receptor for activated C kinase-1 (RACK1) and the requirement for intact cytoskeleton in the process. In astrocytes, Western blots and immunocytochemistry coupled to confocal microscopic quantitative analysis showed that after 5 min of phorbol-12-myristate-13-acetate (PMA) exposure, native PKC-betaII, but not PKC-betaI, is relocated efficiently from the cytosol to the PM. Translocation of PKC-betaII was not associated with synchronous RACK1 relocation. Furthermore, the quantity of PM-associated PKC-betaII that co-immunoprecipitated with PM-bound RACK1 increased following PMA exposure, indicating a post activation binding of the two proteins in the PM. Because RACK1 and PKC-betaII relocation seemed not to be synchronous, we hypothesized that an intermediate interaction with the cytoskeleton was taking place. In fact, we were able to show that pharmacological disruption of actin-based cytoskeleton greatly deranged PKC-betaII translocation to the PM. The requirement for intact actin cytoskeleton was specific, because depolymerization of tubulin had no effect on the ability of the kinase to translocate to the PM. These results indicate that in astrocytes, RACK1 and PKC-betaII synchronous relocation is not essential for relocation of PKC-betaII to the PM. In addition, we show for the first time that the integrity of the actin cytoskeleton plays a specific role in PKC-betaII movements in these cells. We hypothesize that in glial cells, rapidly occurring changes of actin cytoskeleton arrangement may be involved in the fast reprogramming of PKC targeting to specific PM location to phosphorylate substrates in different cellular locations. Published 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042584     DOI: 10.1002/glia.10354

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  6 in total

1.  Identification of novel small molecule activators of nuclear factor-κB with neuroprotective action via high-throughput screening.

Authors:  Marina S Manuvakhova; Guyla G Johnson; Misti C White; Subramaniam Ananthan; Melinda Sosa; Clinton Maddox; Sara McKellip; Lynn Rasmussen; Krister Wennerberg; Judith V Hobrath; E Lucile White; Joseph A Maddry; Maurizio Grimaldi
Journal:  J Neurosci Res       Date:  2011-01       Impact factor: 4.164

2.  Tagging of functional ribosomes in living cells by HaloTag® technology.

Authors:  Simone Gallo; Anne Beugnet; Stefano Biffo
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-11-17       Impact factor: 2.416

3.  Diabetes-induced increased oxidative stress in cardiomyocytes is sustained by a positive feedback loop involving Rho kinase and PKCβ2.

Authors:  Hesham Soliman; Anthony Gador; Yi-Hsuan Lu; Guorong Lin; Girish Bankar; Kathleen M MacLeod
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-03       Impact factor: 4.733

4.  Changes in gene expression and cellular architecture in an ovarian cancer progression model.

Authors:  Amy L Creekmore; William T Silkworth; Daniela Cimini; Roderick V Jensen; Paul C Roberts; Eva M Schmelz
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

5.  PKCβII acts downstream of chemoattractant receptors and mTORC2 to regulate cAMP production and myosin II activity in neutrophils.

Authors:  Lunhua Liu; Derek Gritz; Carole A Parent
Journal:  Mol Biol Cell       Date:  2014-03-05       Impact factor: 4.138

Review 6.  Redox Modulations, Antioxidants, and Neuropsychiatric Disorders.

Authors:  Erik A Fraunberger; Gustavo Scola; Victoria L M Laliberté; Angela Duong; Ana C Andreazza
Journal:  Oxid Med Cell Longev       Date:  2015-11-10       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.